POM stock forecast, quote, news & analysis
Pomdoctor Ltd is an online medical services platform for chronic diseases in China... Show more
Why PomDoctor Limited (POM) Stock Is Up +80% in the Last 30 Days
Key Takeaways
- POM shares have surged roughly 80% over the trailing 30 days, climbing from about $0.96 in late September to approximately $1.73 in late October 2026.
- The move coincides with PomDoctor's termination of its American Depositary Receipt (ADR) program and the direct listing of its Class A ordinary shares on Nasdaq, which triggered a sharp spike in trading volume.
- The stock remains exceptionally volatile, with a 52-week range of roughly $0.43 to $115.74, reflecting its profile as a speculative micro-cap healthcare name.
- Fundamentals remain under pressure, with negative net income and negative operating margins on trailing twelve-month revenue of about $410 million.
- Over the past quarter, the stock has more than doubled from levels near $0.80 in early August, though it still trades far below its post-IPO highs.
- Explore PomDoctor's Price Targets, Earnings, and Forecast for additional data and analysis on the ticker.
- Explore Trending AI Robots to see top-performing AI trading bots across the market.
PomDoctor Limited (POM) Company Overview and Market Position
PomDoctor Limited is a China-based online medical services platform focused on chronic disease management and pharmaceutical services. Operating primarily through two segments — an internet hospital and a pharmaceutical supply chain — the company connects patients, doctors, pharmacies, suppliers, and other healthcare participants on a single digital platform. Headquartered in Guangzhou, China, the company went public on Nasdaq in October 2025 at an IPO price of $4.00 per share.
PomDoctor's business model centers on a B2C portal that facilitates the sale of pharmaceutical products alongside online medical consultation services. Investors follow the stock for its exposure to China's digital healthcare and chronic disease management sector, though the company's small float, negative earnings, and recent share-structure changes make it a high-volatility name.
PomDoctor Limited (POM) Stock Price Performance: Last 30 Days vs. Quarter
Over the trailing 30 days, POM has advanced approximately 80%, rising from a closing price near $0.96 on September 30, 2026, to roughly $1.73 in late October. The move has been anything but linear: the stock experienced extreme intraday swings, including a single-session jump to $3.01 in mid-October on unusually heavy volume before settling back into the $1.70-to-$2.00 range.
The broader quarterly picture is similarly dramatic. From levels near $0.80 in early August, POM has more than doubled, gaining well over 100% across the period. This rebound stands in sharp contrast to the stock's longer-term trajectory, which remains deeply negative after the share price fell more than 97% from its 52-week high of $115.74 to a low near $0.43.
What Drove POM Stock Price in the Last 30 Days
The dominant catalyst behind the recent surge was corporate restructuring rather than operating performance. In mid-October 2026, PomDoctor announced the commencement of its ADR program termination and the planned direct listing of its Class A ordinary shares on Nasdaq under the symbol "POM." This transition of the listing structure prompted a dramatic increase in trading activity, with daily volume spiking into the tens of millions of shares and extreme price volatility following the announcement.
Beyond the share-structure change, the move reflects the mechanics of a thinly traded micro-cap where liquidity is limited and sentiment can shift rapidly. The stock's price action in late October — including repeated double-digit percentage moves within single sessions — underscores the elevated speculative activity surrounding the name during its transition to direct listing.
What Drove POM Stock Performance Over the Last Quarter
The quarterly trend reflects a longer narrative of post-IPO turbulence followed by a sharp, restructuring-driven rebound. After its October 2025 debut at $4.00, POM traded in a wide range and ultimately declined substantially, with the share price eroding toward sub-$0.50 levels by mid-October 2026. The subsequent announcement to end the ADR program and move to a direct listing of ordinary shares marked a pivotal event, re-pricing the stock and drawing renewed speculative interest.
Investors have also been weighing the company's financial profile throughout the period. PomDoctor has reported substantial net losses and negative operating margins, while carrying a heavy debt load relative to its limited cash position. These fundamentals have kept the stock in a high-risk category, even as the listing transition temporarily redirected attention toward the share structure rather than operating results.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots from a platform that offers hundreds of automated strategies across thousands of tickers. Only the top-performing and most relevant bots appear in this section, and each bot varies in its approach, trading timeframe, and performance metrics. For traders seeking a systematic, data-driven way to monitor market conditions, exploring these tools can provide additional perspective on how automated strategies are navigating volatile names and broader market trends.
POM Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, several factors are likely to shape POM's path. The company's next earnings report is anticipated in early November 2026, and investors will focus on revenue trends, margin improvement, and any updates on the company's cash position and debt obligations. As a China-based healthcare platform, PomDoctor is also exposed to domestic regulatory and policy developments affecting digital healthcare and pharmaceutical distribution.
The completion of the direct-listing transition will be closely watched, as the new share structure could influence float, liquidity, and institutional participation. Given the stock's recent volatility and strained profitability, price discovery is likely to remain choppy. Investors should monitor trading volume, share-count disclosures, and any financing announcements as key signals of the stock's near-term direction.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
POM in upward trend: price rose above 50-day moving average on October 21, 2026
POM moved above its 50-day moving average on October 21, 2026 date and that indicates a change from a downward trend to an upward trend. In 3 of 3 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 8 of 10 cases where POM's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on POM as a result. In 15 of 19 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for POM just turned positive on October 21, 2026. Looking at past instances where POM's MACD turned positive, the stock continued to rise in 4 of 7 cases over the following month. The odds of a continued upward trend are 57%.
The 10-day moving average for POM crossed bullishly above the 50-day moving average on October 21, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 2 of 2 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +43.16% 3-day Advance, the price is estimated to grow further. Considering data from situations where POM advanced for three days, in 56 of 63 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
Bearish Trend Analysis
The 10-day RSI Indicator for POM moved out of overbought territory on October 22, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 4 similar instances where the indicator moved out of overbought territory. In 4 of the 4 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where POM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
POM broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 29 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: POM's P/B Ratio (0.000) is slightly lower than the industry average of (1.425). P/E Ratio (0.000) is within average values for comparable stocks, (-2.228). POM's Projected Growth (PEG Ratio) (0.000) is very low in comparison to the industry average of (0.947). Dividend Yield (0.000) settles around the average of (0.254) among similar stocks. P/S Ratio (0.043) is also within normal values, averaging (2.504).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. POM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. POM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 100, placing this stock worse than average.
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry DrugstoreChains